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Abstract
Background: The goal was to determine whether one medical centres’ unique antifungal prophylactic regimen for
patients at high risk for invasive candidiasis because of their haematological malignancies, haematopoietic stem cell
transplants, or high-dose chemotherapy might lead ultimately to a higher incidence of infection, to increasing
fluconazole resistance, or to a shift in the predominant strain of Candida in invasive fungal episodes.
Methods: Data were collected retrospectively, for a ten-year period from ONKO-KISS surveillance records, and from
hospital, medical, and pharmacy records and then evaluated with respect to incidence of fungal infection episodes,
emergence of antifungal drug resistance, and predominance of specific Candida strains in isolate cultures. Fisher’s
exact test and linear regression were used to compare minimum inhibitory concentrations and to compare the
incidence of different Candida isolates, respectively.
Results: The incidence of infection remained quite stable over 10 years with a median of 0.67 episodes/1000 bed
days. Overall, Candida glabrata was the predominant species with 29% followed by C. albicans and C. krusei
(14% each). No significant increment of non-albicans Candida species with decreased fluconazole susceptibility
was perceived over this decade.
Conclusions: Once weekly administration of 400 mg of fluconazole to prevent candidaemia appears to have no
negative impact on the efficacy as a prophylaxis when compared to standard of care (400 mg of fluconazole daily).
Background
The incidence of invasive candidiasis in patients who
have haematological malignancies or who are recipients
of haematopoietic stem cell transplants (HSCTs) has
decreased over the past few decades, in particular because
of the antifungal prophylactic use of triazoles. However,
invasive candidiasis is the most common invasive fungal
infection in the early phase of recovery after HSCT,
and remains the second most common invasive fungal
infection after invasive aspergillosis in patients with
graft-versus-host disease (GvHD). Invasive candidiasis
still causes significant morbidity and attributable mor-
tality in these patients; therefore, adequate antifungal
prophylaxis is crucial for them [1-3]. Finding an
optimum antifungal prophylaxis remains an on-going
goal. Studies have suggested that fluconazole doses
below 400 mg/day may reduce only superficial fungal
infections but have limited efficacy in preventing invasive
candidiasis [4,5]. However, a small retrospective analysis
in 2001 of antifungal prophylaxis using 100–200 mg of
fluconazole per day in patients undergoing bone marrow
transplantation showed the incidence of C. glabrata and
C. krusei breakthrough infections to be similar to the
incidence of breakthrough infections reported with doses
of 400 mg of fluconazole per day and a randomized
controlled trial conducted with children and adult patients
undergoing HSCT comparing 200 mg versus 400 mg of
fluconazole per day demonstrated similar efficacy in
reducing superficial and systemic infection with Candida
species with both regimens [6,7].
Once daily dosing of 400 mg of fluconazole has
been used as prophylaxis against invasive candidiasis
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for patients in profound neutropenia since many years and
is a result of various randomized placebo-controlled trials
[8-10]. The Centers for Disease Control and Prevention,
Atlanta, USA (CDC) guidelines advise against the use of
lower fluconazole dosages (between 100–200 mg/day) as
antifungal prophylaxis for HSCT recipients [11].
On the reverse isolation haematology unit (RIHU) at
this hospital the experience with daily non-absorbable
nystatine and amphotericine B was not satisfying with
patient adherence reported to be low. Data with haem-
atological patients in neutropenia have shown that
50 mg of fluconazole daily effectively reduced colonizing
and superficial candida infections [12,13]. Based on these
results, and data derived from HIV patients, which showed
that weekly dosages of 150 mg sufficiently prevent oro-
pharyngeal candidiasis [14,15], a once weekly prophy-
laxis of fluconazole 400 mg was thought to equally
reduce colonizing Candida species in our haematology
patients and therefore, prevent invasive infection from
this species during severe immunosuppression with the
advantage of better tolerance and acceptance by the pa-
tient, less drug interactions, and a minor shift towards
invasive non-albicans Candida species.
For this reason, the division of haematology instituted
a change in the antifungal prophylaxis regimen policy in
the 1990s for patients during aplasia after they had
undergone high-intensity chemotherapy, or an autologous
HSCT, and for patients who were immunosuppressed
after undergoing an allogeneic HSCT. The policy specified
administering 400 mg of fluconazole once a week, rather
than once per day. This extraordinary prophylaxis was
then combined with a diagnostic driven pre-emptive
treatment strategy in cases of suspected fungal infec-
tion, at which time fluconazole prophylaxis is replaced
by antifungal treatment with caspofungin or voricona-
zole. Regarding the incidence of invasive fungal infec-
tions overall, this latter strategy thus far has proven safe
for patients undergoing allogeneic HSCT at the medical
centre [16].
There are, however, unanswered questions with respect
to the possible emergence of resistance to fluconazole over
time and the persistent lack of evidence of effectiveness
for this exceptional prophylactic regimen. In contrary,
evidence has been increasing that routine prophylaxis
with 400 mg fluconazole per day may lead either to an
increase in fluconazole resistance, and an increase in
the minimum inhibitory concentrations (MICs) of anti-
fungal agents that are necessary to be effective against
Candida species or to a shift from predominantly
Candida albicans toward other less fluconazole suscep-
tible Candida species in episodes of invasive candidiasis
[17,18]. The elimination half-life of fluconazole is around
30 hours. This results in sub-inhibitory concentrations
after only a few days, implicating that there might be an
even greater possibility of increasing emergence of resist-
ance at fluconazole doses of 400 mg per week.
Therefore, the goal of this study was to determine
whether the hospital’s antifungal prophylactic regimen
for patients at high risk for invasive candidiasis might be
leading to increased resistance to fluconazole or to a shift
toward other strains of Candida sp. and, thus, to gradually
reduce efficacy for these patients.
Methods
The setting for this study is one of the three largest stem
cell transplantation units in Switzerland at a 700-bed pri-
mary and tertiary care hospital performing both allogeneic
and autologous HSCT. The RIHU at the University
Hospital Basel, Switzerland is located in a closed wing
and provides a protected environment for patients that
are undergoing HSCTs or high-dose chemotherapy. The
unit is equipped with laminar air flow, has restricted
access, and has a dedicated staff that wears gowns,
masks, and gloves whenever entering the patients’
rooms. Patients admitted to the RIHU are placed in
single-occupancy rooms until neutrophil recovery.
We analysed a cohort of patients hospitalized on RIHU
between 1 January 2003 and 31 December 2012. The
study used data collected within the framework of the
medical centre’s participation in the German nosocomial
infection surveillance system (Krankenhaus Infektions
Surveillance System), which was initiated in 2000 and
focuses on nosocomial sepsis and pneumonia in patients
with haematological malignancies (known as ONKO-KISS)
and prospectively collects data from patients during their
episode of neutropenia [19]. The RIHU of the University
Hospital Basel has participated in ONKO-KISS since
July 2003. The characteristics of the remaining patients
hospitalised in RIHU from January 2003 through June
2003 are therefore missing. Case report forms provided
the prospectively recorded ONKO-KISS information in-
cluding demographics, underlying disease and treatment
regimens. Detailed information about the patients with
invasive candidiasis was retrieved from the hospital’s
medical records and from the hospital’s microbiology
laboratory as not all these patients were concomitantly
in neutropenia and/or underwent HSCT during their
hospitalisation with invasive candidiasis and were, there-
fore, not recorded in ONKO-KISS. Data included general
demographic information, the duration of RIHU stays, in-
formation about Human Leukocyte Antigen (HLA)-typing
and donor relatedness, the number and type of HSCT,
underlying disease or condition, treatment regimens,
serostatus of cytomegalovirus (CMV) and CMV infec-
tion, incidence of graft-versus-host disease (GvHD), in-
cidence of invasive candidiasis, duration of neutropenia,
duration of hospitalisation in the Intensive Care Unit
(ICU), and deaths within 30 days after a diagnosis of
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invasive candidiasis as well as results of cultures that
identified invasive candidiasis strains, the date of specimen
entry into the laboratory, and the corresponding resistance
testing.
Data on the use of antifungal consumption were available
from the hospital’s central pharmacy from January
2004 onward. Antifungal consumption was measured
as a defined daily dose (DDD) per 100 patient days
(PD). Defined daily doses (DDD) of antifungal drugs
were calculated according to published World Health
Organization (WHO) guidelines and reflect the assumed
average maintenance dose per day for a drug used for its
main indication in adults [20].
Candida bloodstream infections and disseminated can-
didiasis were defined according to the European Organisa-
tion for Research and Treatment in Cancer (EORTC)
criteria [21,22]. Specifically, invasive candidiasis was de-
fined as the isolation of a Candida species from a sterile
specimen. All Candida isolates were identified in the
hospital’s microbiology laboratory. Only the first episode
in a patient with a mono-microbial infection was counted.
Positive cultures of Candida species from urine, from
rectal and oral swabs, or from respiratory secretions were
always interpreted as colonisation. There is no systematic
surveillance for Candida colonisation as part of ONKO-
KISS; therefore, any recorded results from non-sterile
specimens were not included in this analysis.
A panfungal polymerase chain reaction (PCR) assay
that was developed in the hospital’s Clinical Microbiology
Laboratory was used to verify the presence of clinically
suspected candidiasis in a biopsy specimen when a blood
culture remained negative. This PCR-assay uses ITS5 and
ITS4 primers for amplification of ITS region 1 and region
2, followed by sequencing for species identification [23].
Prior to 2007, blood cultures were processed by using the
automated BacT/ALERT® system. Since 2007, the BacT/
ALERT 3D® Microbial Detection System (bioMérieux,
Durham, North Carolina, USA) was used and the FA aer-
obic and FN anaerobic bottles processed according to the
manufacturer’s instructions. Candida strains were identi-
fied by using standard microbiology techniques, including
the use of the ID 32 C identification system (bioMérieux,
Marcy-l’Étoile, France). From January 2003 through
December 2004, MICs of antifungal drugs with respect
to strains of Candida in samples were determined in
an external microbiology laboratory that was affiliated
with the University. Thereafter, the antifungal drug MICs
were determined in the hospital’s Clinical Microbiology
Laboratory by using the Sensititre YeastOne® colorimet-
ric antifungal panel (TREK Diagnostic Systems Inc.,
Cleveland, Ohio, USA) and interpreted according to the
2008 breakpoints defined by the Clinical and Laboratory
Standards Institute (CLSI), formerly known as the National
Committee for Clinical Laboratory Standards (NCCLS).
Fisher’s exact test was used to compare the fluconazole
susceptibility defined as MIC < or equal to 8 mg/L for all
invasive Candida strains. We also compared the MICs
of invasive C. albicans and C. glabrata strains respectively.
Estimating a trend for C. krusei seemed not appropriate to
us as three of the four strains with the same MIC occurred
within the same year. Linear regression was applied to
compare the incidence of different Candida isolates. Two-
tailed p-values <0.05 were considered significant. Analyses
were performed by using SPSS Statistical Software Version
21.0. The number of positive cultures in this study was




We had a total of 899 patients who were at least once hos-
pitalized in the RIHU from January 2003 until December
2012. These patients spent a mean of 3977 bed days (BD)
per year in the RIHU with a median duration of 26 days in
the RIHU per patient (IQR 18–33). From July 2003
through December 2012, 753 of the 899 patients became
registered in the ONKO-KISS as being neutropenic and
underwent HSCT or, from 2008 onwards, were included
because of their induction or consolidation chemotherapy.
Most of them suffered from acute myeloid leukaemia.
612 were admitted for allogeneic or autologous stem
cell transplantations and 134 were admitted for high-
dose chemotherapies. Chemotherapy regimens included
induction, re-induction, and consolidation chemother-
apy (See Table 1 for patient characteristics of the RIHU
ONKO-KISS population).
Incidence and susceptibility of Candida species
There were a total of 28 invasive candidiasis episodes
within 28 patients during this decade. The average age of
these patients was 47 years. The majority (16/28; 57%) of
these patients suffered from acute myeloid leukaemia
(AML), and most patients underwent allogeneic HSCT
(Table 2). Among the 612 HSCT recipients on RIHU
candidaemia occurred in 4.6% corresponding to 4.6 candi-
daemia episodes per 100 transplantations (Tables 1 and 2).
Two patients were each infected during one hospitalisa-
tion period with two different strains of Candida species
and were therefore excluded from analysis. Candida
species were isolated from blood cultures (n = 26), a
skin biopsy (n = 1), and a liver biopsy (n = 1).
The analysis of the 28 invasive candidiasis strains
revealed 8 C. glabrata (29%), 4 C. albicans (14%), and 4 C.
krusei (14%) as the most common strains (Table 2). Other
species that were less often found included C. norvegensis
(11%), C. inconspicua, C. dubliensis, and C. parapsilosis
(7% each), C. kefyr, and C. guilliermondii, and C. tropicalis
(4% each).
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Only one haematology patient in this study suffered
from hepato-splenic candidiasis. The culture from the
patient’s liver biopsy remained negative, but the panfungal
PCR assay was positive for C. parapsilosis.
Overall, the median incidence for invasive candidiasis
was 0.67 per 1000 bed days (IQR 0.47-1.01 per 1000 bed
days) and we were unable to demonstrate a significant
increase over the 10 years (Figure 1).
With linear regression analysis we found no sig-
nificant increment in non-albicans Candida species
versus C. albicans alone (p = 0.466). Similarly, when
C. glabrata and C. krusei were taken together ver-
sus all other Candida species, the linear regression
showed only a mild increase (p = 0.603), despite the
fact that C. glabrata and C. krusei are usually con-
sidered as not susceptible to or intrinsically resist-
ant to fluconazole. However, we found a trend
towards more C. glabrata versus all other Candida
Table 2 Characteristics of the 28 patients with invasive
candidiasis in a single-centre study over 10 years
Total number of invasive candidiasis episodes 28








C. kefyr, C. guilliermondii, C. tropicalis (each 1) 3
Gender
Number of males 12 (42.9%)
Number of females 16 (57.1%)
Median age in years 47 (31–63 IQR)
Underlying conditions:
Number of patients with:
Acute myeloid leukaemia 16
Acute lymphatic leukaemia 3
Myelodysplastic syndrome 3
Non-Hodgkin lymphoma and plasmocytoma (2 each) 4




Number of allogeneic HSCT recipients 15
PBSC recipients 13
BMT recipient 1
Cord blood recipient 1
Related/unrelated donor 1/14 (6.7%/93.3%)
Conditioning chemotherapy before HSCT 2
Induction chemotherapy 8
Other chemotherapies (e.g. consolidation, not specified) 3
Other risk factors for invasive candidiasis
A stay in the ICU within 7 days prior to onset
of invasive candidiasis
4
Number of patients in neutropenia (<500/uL)
at time of invasive candidiasis
19
Median duration (days) of neutropenia until
diagnosis of invasive candidiasis
13 (7–24 IQR)
Number of patients with CMV disease before
invasive candidiasis episode
2




Death (all cause) within 30 days after diagnosis
of invasive candidiasis
10
ICU = intensive care unit.
CMV = Cytomegalovirus.
GvHD = graft-versus-host disease.
Table 1 Baseline characteristics of patients hospitalized
on RIHU and registered in ONKO-KISS from July 2003
through December 2012
Total number of patients 753
Males 458 (60.8%)
Females 295 (39.2%)
Median age in years
Males 49 (38–61 IQR)
Females 50 (38–59 IQR)
Underlying conditions:
Acute myeloid leukaemia 304 (40.4%)
Acute lymphatic leukaemia 97 (12.9%)
Myelodysplastic syndrome 47 (6.2%)
Non-Hodgkin lymphoma 70 (9.3%)
Plasma cell disorders 83 (11%)
Underlying condition not in records 1 (0.1%)
Treatment regimens:
Number of allogeneic HSCT recipients: 440
PBSC recipients 412 (93.6%)
BMT recipients 25 (5.7%)
Cord blood recipients 3 (0.7%)
Donor related/unrelated 242/198 (55.0%/45.0%)
Number of autologous HSCT recipients: 172
Number of patients undergoing induction,
re-induction or conditioning chemotherapy:
123
Other chemotherapies (consolidation
chemotherapy, or treatment not specified
in database)
16
RIHU = reverse isolation haematology unit.
IQR = interquartile range.
HSCT = haematopoietic stem cell transplantation.
PBSC = peripheral blood stem cell.
BMT = bone marrow transplantation.
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species over this decade, but this was not statistically
significant (p =0.124).
In 27 of the 28 isolates it was possible to test for
fluconazole susceptibility. The C. parapsilosis isolate
identified by PCR assay could not be tested because it
did not grow in culture and there is currently no
standard molecular susceptibility method that would
apply to this strain.
No trend toward reduced fluconazole susceptibility
among invasive Candida isolates was found over the
10 years (Figure 2), with susceptibility being defined
according to 2008 CLSI breakpoint definitions that
consider isolates with a MIC of ≥8 mg/L to be non-
susceptible (p = 0.162, 95% CI 0.8651- 3.67). The me-
dian MIC of the most common invasive strains was as
follows (IQR): 0.19 mg/L (0.12 – 0.16 mg/L) for C.
albicans, 12 mg/L (8 – 208 mg/L) for C. glabrata and
128 mg/L (44–128 mg/L) for C. krusei. A trend analysis
did not show a significant increase in MIC. However, the
number of data points precludes a meaningful interpret-
ation of this analysis.
Antifungal consumption
Regarding administration of antifungals at the RIHU we
found that amphotericin B use decreased markedly from
2005 to 2008 (from 50 DDD/100 PD to 3.1 DDD/100
PD) coinciding with an increase of caspofungin use
which has also a certain anti-mould activity but is better
tolerated and less toxic than the deoxycholate form of
amphotericine B. A re-increase in amphotericine use to a
maximum of 38 DDD/100 PD in 2010 was likely due to






































Figure 1 Incidence of invasive Candidiasis on RIHU from 2003–2012. Other Candida species: C. norvegensis, C. inconspicua, C. dubliensis; C.
















Figure 2 Susceptibility* of invasive Candida isolates to fluconazole from 2003–2012. Light grey bars = percentage of susceptible Candida
species. *Susceptibility is defined as a minimum inhibitory concentration (MIC) of < or equal to 8 mg/L (CLSI definition, 2008). CLSI = Clinical and
Laboratory Standards Institute, formerly known as the National Committee for Clinical Laboratory Standards (NCCLS).
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The use of voriconazole over the same time span
exceeded the median amphotericin use slightly with 28.8
DDD/100 PD. Caspofungin consumption increased mark-
edly from 3.5 DDD/100 PD in 2004 to 14.1 DDD/100 PD
in 2006, but its use changed only minimally thereafter.
The level of fluconazole use remained stable (median 22.6
DDD/100 PD) over the course of the study and reflects
prophylactic use. Posaconazole was introduced in 2007 as
an antifungal therapeutic agent, but it has rarely been
applied as prophylaxis at this hospital. The consumption
of antifungals is shown in Figure 3.
Discussion
In the most recent European guidelines of the European
Conference on Infections in Leukaemia (ECIL), adminis-
tration of 400 mg fluconazole once daily is graded as an
AI recommendation for HSCT recipients in the initial
neutropenic phase if a mould-directed diagnostic ap-
proach is provided and is graded as a CI recommenda-
tion for patients with chronic GvHD and patients with
acute leukaemia during induction chemotherapy [24].
With intention to reducing morbidity and mortality
due to Candida diseases in HSCT recipients until 100 days
post HSCT fluconazole 400 mg once daily has also been
ascribed an AI recommendation by the European Society
of Clinical Microbiology and Infectious Diseases (ESCMID)
[25]. In the American guidelines 400 mg of fluconazole
once daily has an AI recommendation grade for all patients
with haematological malignancies or who are recipients
of HSCT [26,27]. In several retrospective studies, the
incidence of invasive candidiasis in patients who were
undergoing HSCT varied within a range of 0.9% to 4.6%
depending on the country, the centre where the studies
took place, and the percentage of allograft recipients in
the studies, even though the majority of the studies used
400 mg of fluconazole on a daily basis as antifungal
prophylaxis [1,28]. In this ten-year study, however, we
found a remarkably stable median incidence of invasive
candidiasis with 0.67 per 1000 BD and an incidence of
4.6% among all HSCT recipients using only 400 mg
fluconazole once a week as antifungal prophylaxis. This
finding was unexpected. Albeit there could be several
other factors playing a role in preventing invasive candid-
iasis like the strict reverse isolation practice, optimized
central venous catheter care, or high level of hand hygiene
compliance, but these components did not change
considerably over this time period and, therefore, seem
to play a minor role. We postulate that this weekly
dosage of fluconazole indeed reduces mucocutaneous
colonisation with Candida species during profound
neutropenia and, therefore, preventing sufficiently invasive
candidiasis in a setting with general low prevalence of
invasive fungal infections.
The distribution of Candida species in this analysis
did not vary significantly over the study period, but it
differs from data in other published epidemiological
studies in Europe that involved a 400 mg dose of
fluconazole on a daily basis. Surveillance data from
Europe listed the four most common Candida species
as C. albicans (34.6%), C. glabrata (9.7%), C. parapsilosis
(14.8%), and C. tropicalis (17.9%) in a total of 257 haema-
tology patients [29]. The results of this study also differ
from other studies that used lower daily dosages of flucon-
azole. In Safdar et al. [6], who used a mean fluconazole
dose of 150 mg/day (100–200 mg/day), the distribution
in 15 episodes of candidaemia was C. glabrata (53.3%),
C. krusei (33.3%), C. parapsilosis (13.3%), and no C.
albicans. This study’s distribution in 28 episodes of
invasive candidiasis is C. glabrata (29%), C. albicans (14%),



























Figure 3 Antifungal use on RIHU from 2004–2012 in defined daily dosages (DDD) per 100 patient days. * Liposomal and conventional
(cholesteryl sulfate complex) amphotericin B.
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The mild trend toward a higher incidence of C. glabrata
which is known to be dose dependent fluconazole
susceptible as well as a decreased incidence of invasive
C. albicans in the most recent years is consistent with
other studies, even when their regimens were once-daily
use of fluconazole as a prophylaxis [17,30]. However,
the absence of C. krusei in the last years of the whole
decade is rather unexpected. Admittedly with a small
sample set, it was impossible to demonstrate a signifi-
cant shift towards less fluconazole susceptible species.
This study and the previous study by our colleagues
[16] have shown that this unique regimen of antifungal
prophylaxis (administration of fluconazole on a weekly
basis) in combination with an early diagnostic-driven
approach to treatment for suspected mould infections is
safe and also that it might contribute to a relatively stable
incidence of invasive candidiasis that is consistent with
the incidence over time reported in other studies.
Although it is a single-centre study, it seems to have a
representative cohort of patients that is similar to cohorts
in other studies reported in the literature with patients
registered only when neutropenic and undergoing induc-
tion chemotherapy or HSCT.
The major limitations were the small sample size of
patients with invasive candidiasis precluding us from
providing additional meaningful statistics and that we
lack data on empirical antifungal treatment over the
study period. In addition, there is neither an active nor
a historical control group without prophylaxis with which
we could compare this sample population because of the
strong advice for antifungal prophylaxis. Own former data
about incidence of invasive candidiasis before introdu-
cing this regimen are lacking. There were centres in
Switzerland without providing prophylaxis to their
haemato-oncology patients and centres with different
prophylaxis such as low dosages of liposomal amphoteri-
cin B i.v.; however, the heterogeneity of this population in
important predictors, e.g. absence of allogeneic HSCT,
and that the centres abandoned their strategy or switched
to a different antifungal prophylaxis renders a comparison
of the incidence and distribution of invasive Candida
species with our data difficult. Monitoring of trough levels
of fluconazole was not routinely performed in our hospital.
The strengths of this study therefore are (1) a 10-year
study period that comprises 753 patients at high risk for
invasive candidiasis due to the treatment regimens for
their underlying conditions, and (2) the use of standard-
ized criteria for diagnosing invasive candidiasis, with
97% of the samples verified by a positive culture from a
sterile site.
Conclusions
This unique regimen of administering fluconazole weekly
showed neither a significant increase in the incidence of
invasive candidiasis, or an emergence of fluconazole resist-
ance, nor a significant shift toward non-albicans Candida
species. In upcoming guidelines, the current recommen-
dation for fluconazole prophylaxis in HSCT patients may
be revised due to strong evidence for the use of posacona-
zole and voriconazole as effective prophylactic agents in
this population. But a once weekly dose of fluconazole
may still be a safe and effective alternative prophylaxis that
can potentially reduce exposure to antifungal drugs and
lower drug toxicities and drug interactions in these high-
risk patients provided that the general prevalence of inva-
sive fungal infections in this setting is low.
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